Immunovant's Phase 3 Trials Fail to Meet Primary Endpoints
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy IMVT?
Source: NASDAQ.COM
- Trial Results: Immunovant's Phase 3 trials of Batoclimab for Thyroid Eye Disease failed to meet primary endpoints, resulting in an 8.12% pre-market drop to $23.06, indicating investor concerns about the company's future prospects.
- Treatment Analysis: The trials evaluated a regimen of 680mg of Batoclimab administered subcutaneously once weekly for 12 weeks, followed by 340mg weekly, but failed to achieve a 2mm or greater improvement in proptosis responder rate at Week 24, reflecting insufficient efficacy in this indication.
- Patient Response Insights: Despite not meeting primary endpoints, the studies indicated that patients showed greater proptosis improvement during the initial high-dose phase, suggesting that deeper IgG suppression may positively influence treatment outcomes, which could impact future drug development strategies.
- Future Development Plans: Immunovant intends to review future development plans for Batoclimab with partner HanAll Biopharma and remains focused on advancing IMVT-1402 across multiple autoimmune diseases, with topline data for Graves' disease expected in 2027, demonstrating the company's long-term commitment to this area.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMVT
Wall Street analysts forecast IMVT stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.890
Low
22.00
Averages
37.00
High
54.00
Current: 24.890
Low
22.00
Averages
37.00
High
54.00
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
US Stocks Plummet as Oil Prices Surge
- Oil Price Surge: Crude oil prices soared over 13% as President Trump took a tougher stance on Iran, reaching a 3.5-week high, which not only heightened inflation fears but also pushed bond yields higher, with the 10-year T-note yield rising by 2 basis points to 4.34%.
- Unemployment Claims Drop: Weekly initial unemployment claims unexpectedly fell by 9,000 to 202,000, indicating a stronger labor market than the anticipated increase to 212,000, which could provide support for the stock market amid rising inflation concerns.
- Global Market Decline: Overseas stock markets are lower, with the Euro Stoxx 50 down 2.25%, China's Shanghai Composite down 0.74%, and Japan's Nikkei 225 sharply falling 2.38% from a two-week high, reflecting global economic uncertainty and investor caution.
- Airline Stocks Plummet: Airline stocks are sharply lower as crude oil prices surged over 10%, raising fuel costs; United Airlines and American Airlines Group both fell more than 6%, highlighting the direct impact of rising oil prices on airline profitability.
See More
Immunovant Reports Disappointing Trial Results, Shares Drop
- Clinical Trial Results: Immunovant's two late-stage trials failed to meet the primary endpoint, although patients showed significant improvement in eye bulging during the initial 12-week high-dose treatment, indicating the potential importance of IgG antibody suppression.
- Stock Reaction: Following the disappointing topline results, Immunovant (IMVT) shares fell 12% in pre-market trading, and if this level holds after the opening bell, it would mark the lowest point in nearly four months, reflecting market pessimism about its future prospects.
- Shift in Treatment Focus: Immunovant plans to shift its focus to the development of IMVT-1402, targeting multiple autoimmune diseases with Graves' disease as a priority, and early Phase 2 data suggest this therapy may help modify the disease, with topline results from late-stage studies expected in 2027.
- Intensifying Market Competition: In the same week that Immunovant reported its results, Viridian Therapeutics (VRDN) also announced its Phase 3 results for treating thyroid eye disease, which met its primary goal but showed limited improvements in inflammation, highlighting the competitive intensity in this therapeutic area.
See More
Immunovant's Phase 3 Trials Fail to Meet Primary Endpoints
- Trial Results: Immunovant's Phase 3 trials of Batoclimab for Thyroid Eye Disease failed to meet primary endpoints, resulting in an 8.12% pre-market drop to $23.06, indicating investor concerns about the company's future prospects.
- Treatment Analysis: The trials evaluated a regimen of 680mg of Batoclimab administered subcutaneously once weekly for 12 weeks, followed by 340mg weekly, but failed to achieve a 2mm or greater improvement in proptosis responder rate at Week 24, reflecting insufficient efficacy in this indication.
- Patient Response Insights: Despite not meeting primary endpoints, the studies indicated that patients showed greater proptosis improvement during the initial high-dose phase, suggesting that deeper IgG suppression may positively influence treatment outcomes, which could impact future drug development strategies.
- Future Development Plans: Immunovant intends to review future development plans for Batoclimab with partner HanAll Biopharma and remains focused on advancing IMVT-1402 across multiple autoimmune diseases, with topline data for Graves' disease expected in 2027, demonstrating the company's long-term commitment to this area.
See More
Immunovant Shares Drop 10% After Batoclimab Trial Failure
- Trial Failure Announcement: Immunovant reported that its late-stage program for batoclimab failed to meet the primary endpoint in two Phase 3 trials for thyroid eye disease, resulting in a ~10% drop in premarket shares.
- Stable Safety Data: Despite the trial failures, both studies indicated safety data consistent with previous findings, with no new safety signals, providing a foundation for future research efforts.
- Future Development Plans: The company stated it will share updates on batoclimab's development program after reviewing plans with its South Korean partner, HanAll Biopharma, indicating ongoing commitment to the project.
- Advancement of New Therapy: Immunovant intends to expedite the clinical advancement of IMVT-1402, with topline data from potentially registrational studies for Graves' disease expected next year, showcasing a new strategic direction for the company.
See More
Logos Increases Immunovant Stake to $35 Million
- Significant Stake Increase: Logos Global Management LP purchased an additional 1.1 million shares of Immunovant in Q4 2025, with an estimated transaction value of $24.5 million, reflecting strong confidence in the company's potential.
- Value Growth: By the end of the quarter, Logos' total stake in Immunovant rose to approximately $35 million, indicating a substantial increase driven by both new shares and price appreciation, highlighting its importance in the fund's portfolio.
- Portfolio Allocation Shift: The stake in Immunovant increased from 0.4% to about 2%, which, while not placing it in the top five holdings, signifies a meaningful commitment within a concentrated portfolio, showcasing Logos' focus on the biotech sector.
- Clinical Progress Monitoring: Immunovant is advancing batoclimab across multiple autoimmune indications, with key Phase 3 study results expected in the first half of 2026, which will significantly impact its regulatory trajectory.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
US Stocks Plummet as Oil Prices Surge
- Oil Price Surge: Crude oil prices soared over 13% as President Trump took a tougher stance on Iran, reaching a 3.5-week high, which not only heightened inflation fears but also pushed bond yields higher, with the 10-year T-note yield rising by 2 basis points to 4.34%.
- Unemployment Claims Drop: Weekly initial unemployment claims unexpectedly fell by 9,000 to 202,000, indicating a stronger labor market than the anticipated increase to 212,000, which could provide support for the stock market amid rising inflation concerns.
- Global Market Decline: Overseas stock markets are lower, with the Euro Stoxx 50 down 2.25%, China's Shanghai Composite down 0.74%, and Japan's Nikkei 225 sharply falling 2.38% from a two-week high, reflecting global economic uncertainty and investor caution.
- Airline Stocks Plummet: Airline stocks are sharply lower as crude oil prices surged over 10%, raising fuel costs; United Airlines and American Airlines Group both fell more than 6%, highlighting the direct impact of rising oil prices on airline profitability.
See More
Immunovant Reports Disappointing Trial Results, Shares Drop
- Clinical Trial Results: Immunovant's two late-stage trials failed to meet the primary endpoint, although patients showed significant improvement in eye bulging during the initial 12-week high-dose treatment, indicating the potential importance of IgG antibody suppression.
- Stock Reaction: Following the disappointing topline results, Immunovant (IMVT) shares fell 12% in pre-market trading, and if this level holds after the opening bell, it would mark the lowest point in nearly four months, reflecting market pessimism about its future prospects.
- Shift in Treatment Focus: Immunovant plans to shift its focus to the development of IMVT-1402, targeting multiple autoimmune diseases with Graves' disease as a priority, and early Phase 2 data suggest this therapy may help modify the disease, with topline results from late-stage studies expected in 2027.
- Intensifying Market Competition: In the same week that Immunovant reported its results, Viridian Therapeutics (VRDN) also announced its Phase 3 results for treating thyroid eye disease, which met its primary goal but showed limited improvements in inflammation, highlighting the competitive intensity in this therapeutic area.
See More
Immunovant's Phase 3 Trials Fail to Meet Primary Endpoints
- Trial Results: Immunovant's Phase 3 trials of Batoclimab for Thyroid Eye Disease failed to meet primary endpoints, resulting in an 8.12% pre-market drop to $23.06, indicating investor concerns about the company's future prospects.
- Treatment Analysis: The trials evaluated a regimen of 680mg of Batoclimab administered subcutaneously once weekly for 12 weeks, followed by 340mg weekly, but failed to achieve a 2mm or greater improvement in proptosis responder rate at Week 24, reflecting insufficient efficacy in this indication.
- Patient Response Insights: Despite not meeting primary endpoints, the studies indicated that patients showed greater proptosis improvement during the initial high-dose phase, suggesting that deeper IgG suppression may positively influence treatment outcomes, which could impact future drug development strategies.
- Future Development Plans: Immunovant intends to review future development plans for Batoclimab with partner HanAll Biopharma and remains focused on advancing IMVT-1402 across multiple autoimmune diseases, with topline data for Graves' disease expected in 2027, demonstrating the company's long-term commitment to this area.
See More
Immunovant Shares Drop 10% After Batoclimab Trial Failure
- Trial Failure Announcement: Immunovant reported that its late-stage program for batoclimab failed to meet the primary endpoint in two Phase 3 trials for thyroid eye disease, resulting in a ~10% drop in premarket shares.
- Stable Safety Data: Despite the trial failures, both studies indicated safety data consistent with previous findings, with no new safety signals, providing a foundation for future research efforts.
- Future Development Plans: The company stated it will share updates on batoclimab's development program after reviewing plans with its South Korean partner, HanAll Biopharma, indicating ongoing commitment to the project.
- Advancement of New Therapy: Immunovant intends to expedite the clinical advancement of IMVT-1402, with topline data from potentially registrational studies for Graves' disease expected next year, showcasing a new strategic direction for the company.
See More
Logos Increases Immunovant Stake to $35 Million
- Significant Stake Increase: Logos Global Management LP purchased an additional 1.1 million shares of Immunovant in Q4 2025, with an estimated transaction value of $24.5 million, reflecting strong confidence in the company's potential.
- Value Growth: By the end of the quarter, Logos' total stake in Immunovant rose to approximately $35 million, indicating a substantial increase driven by both new shares and price appreciation, highlighting its importance in the fund's portfolio.
- Portfolio Allocation Shift: The stake in Immunovant increased from 0.4% to about 2%, which, while not placing it in the top five holdings, signifies a meaningful commitment within a concentrated portfolio, showcasing Logos' focus on the biotech sector.
- Clinical Progress Monitoring: Immunovant is advancing batoclimab across multiple autoimmune indications, with key Phase 3 study results expected in the first half of 2026, which will significantly impact its regulatory trajectory.
See More
